Compare Ascendis Pharma A/S (ASND) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Transocean Ltd — how do they compare? Ascendis Pharma A/S trades at $263.68 (market cap $17.74B), while Transocean Ltd trades at $5.25 (market cap $5.76B). The key difference: Ascendis Pharma A/S is far larger — about 3.1× Transocean Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | RIG | |
|---|---|---|
Market Cap | $17.74B | $5.76B |
Sector | Health | Technology |
52-Week High | $277.18 | $7.58 |
52-Week Low | $163.32 | $2.55 |
Enterprise Value | $18.11B | $10.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Transocean Ltd. (RIG) trades at $5.20, up 1.17% today, with a bearish technical signal and mixed earnings history. The company reported a net loss of -$2.92 billion for 2025 but maintains strong revenue of $3.97 billion and a gross margin of 84.88%. Recent news highlights a $1 billion contract with Equinor and a pending merger with Valaris, aimed at reducing leverage and unlocking synergies.
The outlook is cautiously optimistic, with analyst consensus pointing to a $7.00 price target and 39% buy ratings. Key opportunities include backlog growth and merger benefits, while risks involve persistent net losses, oil price volatility, and execution challenges. The stock's valuation appears attractive with a P/B of 0.7, but profitability remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
